This Article Full Text Full Text (PDF) All Versions of this Article: 105/20/2341    most recent 01.CIR.0000017634.00171.24v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pfeffer, M. A. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Pfeffer, M. A. Articles by Braunwald, E. Related Collections Chronic ischemic heart disease Lipids Cardiovascular Pharmacology Compliance/Adherence Primary prevention Secondary prevention

(Circulation. 2002;105:2341.)
© 2002 American Heart Association, Inc.

Clinical Investigation and Reports

Safety and Tolerability of Pravastatin in Long-Term Clinical Trials

Prospective Pravastatin Pooling (PPP) Project

Marc A. Pfeffer, MD, PhD; Anthony Keech, MD; Frank M. Sacks, MD; Stuart M. Cobbe, MD; Andrew Tonkin, MD; Robert P. Byington, PhD; Barry R. Davis, MD, PhD; Carola P. Friedman, MD; Eugene Braunwald, MD

From the Brigham and Women’s Hospital, Boston, Mass (M.A.P, F.M.S, E.B.); University of Sydney, Camperdown, Australia (A.K.); University of Glasgow, Glasgow, UK (S.M.C.); National Heart Foundation of Australia, Victoria, Australia (A.T.); Section of Epidemiology, Wake Forest University, Winston-Salem, NC (R.P.B.); University of Texas Health Science Center at Houston (B.R.D.); and Bristol-Myers Squibb Company, Hillside, NJ (C.P.F.).

Correspondence to Dr Marc Pfeffer, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail mpfeffer{at}rics.bwh.harvard.edu

Background— Therapeutic decisions regarding pharmacological therapy should be based on safety and tolerability as well as efficacy data. Clinical trials designed to assess efficacy are often insufficiently powered to generate reliable safety data.

Methods and Results— The West of Scotland Coronary Prevention Study (WOSCOPS), the Cholesterol and Recurrent Events (CARE), and Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) studies collectively accumulated >112 000 person-years of exposure in double-blind randomized trials comparing placebo and pravastatin (40 mg once daily). During 5 years of exposure, the incidence of fatal and nonfatal cancers was similar between pravastatin and placebo groups. No differences in noncardiovascular serious adverse events were detected. With >243 000 blood sample analyses, the percentage of patients with any abnormal liver function test after baseline sampling was similar (>3x the upper limit of normal for alanine aminotransferase: 128 [1.4%] versus 131 [1.4%] patients for pravastatin versus placebo, respectively). Study medication was withdrawn in 3 pravastatin and 7 placebo patients due to creatine phosphokinase elevations; no cases of mild or severe myopathy were reported. A Cox regression model considering treatment group, age, diabetes, smoking, whether primary or secondary prevention study, and cardiovascular serious adverse events indicates that the likelihood of discontinuing pravastatin was less than placebo.

Conclusions— This prospective analysis indicates that during prolonged exposure, 40 mg of pravastatin is well tolerated, with no excess of noncardiovascular serious adverse events, including liver function abnormalities and laboratory and clinical evidence for myositis. These extensive safety and tolerability data provide important information for therapeutic decisions regarding this pharmacological agent.

Key Words: statins • pravastatin • safety • rhabdomyolysis • myositis

This article has been cited by other articles:

				J. Afilalo, G. Duque, R. Steele, J. W. Jukema, A. J.M. de Craen, and M. J. Eisenberg Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 37 - 45. [Abstract] [Full Text] [PDF]

				K. Kim Statin and Cancer Risks: From Tasseomancy of Epidemiologic Studies to Meta-Analyses J. Clin. Oncol., October 20, 2006; 24(30): 4796 - 4797. [Full Text] [PDF]

				R. Arora, M. Liebo, and F. Maldonado Statin-Induced Myopathy: The Two Faces of Janus Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 105 - 112. [Abstract] [PDF]

				J. Fortuny, S. de Sanjose, N. Becker, M. Maynadie, P. L. Cocco, A. Staines, L. Foretova, M. Vornanen, P. Brennan, A. Nieters, et al. Statin Use and Risk of Lymphoid Neoplasms: Results from the European Case-Control Study EPILYMPH. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 921 - 925. [Abstract] [Full Text] [PDF]

				W. Rief, J. Avorn, and A. J. Barsky Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects Arch Intern Med, January 23, 2006; 166(2): 155 - 160. [Abstract] [Full Text] [PDF]

				M. P. Solano and R. B. Goldberg Lipid Management in Type 2 Diabetes Clin. Diabetes, January 1, 2006; 24(1): 27 - 32. [Abstract] [Full Text] [PDF]

				S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies J. Clin. Oncol., December 1, 2005; 23(34): 8606 - 8612. [Abstract] [Full Text] [PDF]

				C. P. Cannon The IDEAL Cholesterol: Lower Is Better JAMA, November 16, 2005; 294(19): 2492 - 2494. [Full Text] [PDF]

				I. S. Young Lipids for Psychiatrists - an overview J Psychopharmacol, November 1, 2005; 19(6_suppl): 66 - 75. [Abstract] [PDF]

				S. D. Wiviott, C. P. Cannon, D. A. Morrow, K. K. Ray, M. A. Pfeffer, E. Braunwald, and for the PROVE IT-TIMI 22 Investigators Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy: A PROVE IT-TIMI 22 Substudy J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1411 - 1416. [Abstract] [Full Text] [PDF]

				J. N. Poynter, S. B. Gruber, P. D.R. Higgins, R. Almog, J. D. Bonner, H. S. Rennert, M. Low, J. K. Greenson, and G. Rennert Statins and the Risk of Colorectal Cancer N. Engl. J. Med., May 26, 2005; 352(21): 2184 - 2192. [Abstract] [Full Text] [PDF]

				E. Hawk and J. L. Viner Statins and Cancer -- Beyond the "One Drug, One Disease" Model N. Engl. J. Med., May 26, 2005; 352(21): 2238 - 2239. [Full Text] [PDF]

				B. M. Psaty, C. D. Furberg, W. A. Ray, and N. S. Weiss Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis JAMA, December 1, 2004; 292(21): 2622 - 2631. [Abstract] [Full Text] [PDF]

				C. J. Vaughan and A. M. Gotto Jr Update on Statins: 2003 Circulation, August 17, 2004; 110(7): 886 - 892. [Full Text] [PDF]

				F. M. Sacks High-Intensity Statin Treatment for Coronary Heart Disease JAMA, March 3, 2004; 291(9): 1132 - 1134. [Full Text] [PDF]

				M. Pirmohamed and R. E Ferner Monitoring drug treatment BMJ, November 22, 2003; 327(7425): 1179 - 1181. [Full Text] [PDF]

				F. M. Sacks Reply J. Am. Coll. Cardiol., July 16, 2003; 42(2): 399 - 399. [Full Text] [PDF]

				A. M. Gotto Jr Safety and Statin Therapy: Reconsidering the Risks and Benefits Arch Intern Med, March 24, 2003; 163(6): 657 - 659. [Full Text] [PDF]

				F. M. Sacks Low-density lipoprotein lowering therapy: an analysis of the options J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2135 - 2138. [Full Text] [PDF]